New heart failure drug candidate passes first safety hurdle in obese volunteers
NCT ID NCT07186946
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a single dose of the investigational drug THRV-1268 in 16 healthy obese adults to see if it is safe and tolerable. The drug is being developed as a potential treatment for heart failure. The study did not test effectiveness, only safety and how the drug moves through the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- THRV-1268
- What this could lead to
- If safe, this could lead to larger trials testing whether THRV-1268 helps control heart failure in people with obesity.
- What could go wrong
- This is a very early Phase 1 safety study with only 16 healthy people. It does not test if the drug works for heart failure, and many early drugs fail in later stages.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dr. Vince Clinical Research
Overland Park, Kansas, 66212, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital nurse companion: could an app ease the burden of chronic illness?
- Could continuing a common heart drug before surgery save lives?
- Poles apart? nordic walking may outpace standard rehab for heart failure
- Could a gentler tug on the Heart's reins spark recovery?
- Can slow breathing soothe a failing heart?
- Can shedding pounds reboot the Heart's exercise engine?